Multiple sclerosis classification: Difference between revisions
No edit summary |
No edit summary |
||
| Line 15: | Line 15: | ||
[[Multiple sclerosis]] may be classified according to [[clinical]] course into four groups:<ref name=":0">Lublin FD; Reingold SC. ''Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.'' Neurology 1996 Apr;46(4):907-11. PMID 8780061</ref> | [[Multiple sclerosis]] may be classified according to [[clinical]] course into four groups:<ref name=":0">Lublin FD; Reingold SC. ''Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.'' Neurology 1996 Apr;46(4):907-11. PMID 8780061</ref> | ||
;'''Relapsing remitting:''' | ;'''_ Relapsing remitting:''' | ||
[[RRMS]] is defined by acute attacks of [[neurological]] [[dysfunction]] followed by full or partial [[recovery]]. Patient clinical [[symptoms]] are stable between the attacks.<ref name=":0" /> | [[RRMS]] is defined by acute attacks of [[neurological]] [[dysfunction]] followed by full or partial [[recovery]]. Patient clinical [[symptoms]] are stable between the attacks.<ref name=":0" /> | ||
;'''Secondary progressive:''' | ;'''_ Secondary progressive:''' | ||
Patient with long term [[RRMS]] can switch to [[SPMS]], when the [[neurological]] [[symptoms]] progressively worsen between the attacks.<ref name=":0" /> | Patient with long term [[RRMS]] can switch to [[SPMS]], when the [[neurological]] [[symptoms]] progressively worsen between the attacks.<ref name=":0" /> | ||
;'''Primary progressive:''' | ;'''_ Primary progressive:''' | ||
[[PPMS]] is defined by continuously worsening of [[neurological]] [[dysfunction]] with no distinct attacks and [[remission]]<nowiki/>s.<ref name=":0" /> | [[PPMS]] is defined by continuously worsening of [[neurological]] [[dysfunction]] with no distinct attacks and [[remission]]<nowiki/>s.<ref name=":0" /> | ||
; '''Progressive relapsing:''' | ; '''_ Progressive relapsing:''' | ||
[[PRMS]] is defined by progression of [[disease]] from the beginning with acute attack episodes.<ref name=":0" /> | [[PRMS]] is defined by progression of [[disease]] from the beginning with acute attack episodes.<ref name=":0" /> | ||
Revision as of 10:52, 21 January 2018
|
Multiple sclerosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Multiple sclerosis classification On the Web |
|
American Roentgen Ray Society Images of Multiple sclerosis classification |
|
Risk calculators and risk factors for Multiple sclerosis classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Multiple sclerosis may be classified into four groups according to clinical course of the disease.
- Relapsing-remitting
- secondary-progressive
- primary-progressive
- progressive-relapsing
Classification
Multiple sclerosis may be classified according to clinical course into four groups:[1]
- _ Relapsing remitting:
RRMS is defined by acute attacks of neurological dysfunction followed by full or partial recovery. Patient clinical symptoms are stable between the attacks.[1]
- _ Secondary progressive:
Patient with long term RRMS can switch to SPMS, when the neurological symptoms progressively worsen between the attacks.[1]
- _ Primary progressive:
PPMS is defined by continuously worsening of neurological dysfunction with no distinct attacks and remissions.[1]
- _ Progressive relapsing:
PRMS is defined by progression of disease from the beginning with acute attack episodes.[1]
These subtypes were defined In 1996 by the US National Multiple Sclerosis Society (NMSS).[1]
In recent studies a new subtype recognized and named: clinically isolated syndrome (CIS). It is when the clinical presentation of a disease is suggestive of myelin sheath inflammation but cannot fulfill the diagnostic criteria of MS.[2]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Lublin FD; Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996 Apr;46(4):907-11. PMID 8780061
- ↑ Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH (2014). "Defining the clinical course of multiple sclerosis: the 2013 revisions". Neurology. 83 (3): 278–86. doi:10.1212/WNL.0000000000000560. PMC 4117366. PMID 24871874.